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Background: Currently GnRH analogue injections are used to prevent premature LH surges in women undergoing
assisted reproductive technology. This was a pilot study to determine the safety and effectiveness of nimodipine,
an oral calcium channel blocker, to delay the mid-cycle spontaneous LH surge in women with regular menstrual
cycles.
Methods: Eight women with regular menstrual cycles self-monitored three consecutive cycles for the day of an LH
surge by daily urine assay. The first and third cycles were observatory. In the second cycle, subjects took nimodipine
60 mg by mouth three times daily for four days, starting two days prior to the expected LH surge day based on
cycle one.
Results: The LH surge day in cycle 2 (nimodipine) was significantly delayed in comparison to both observatory
cycle 1 (15.5+/−3.4 vs 14.0+/−2.8 days; p = 0.033) and cycle 3 (15.1+/−3.5 vs 13.1+/−2.4 days; p = 0.044). There was
no difference in the LH surge day between the two observatory cycles (13.4+/−2.4 vs 13.1+/−2.4 days; p = 0.457).
Three patients experienced a mild headache.
Conclusions: There was a statistically significant delay in the spontaneous LH surge day in the treatment cycle in
comparison to both observatory cycles. Nimopidine should be further investigated as an oral alternative to delay a
spontaneous LH surge.
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In reproductive-aged women regular menstrual cycles
usually generate one mature ovarian follicle every month.
In mid-cycle, a natural surge of luteinizing hormone (LH)
and follicle stimulating hormone (FSH) is observed and
predictably induces ovulation within approximately
36 hours. A critical step in the in-vitro fertilization (IVF)
process is the properly timed aspiration of mature follicles
prior to ovulation. Historically spontaneous ovulation was
the major cause of treatment cancellation, occurring in up
to 20% of cases, even in unstimulated IVF cycles [1].* Correspondence: casper@lunenfeld.ca
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reproduction in any medium, provided the orFurthermore, a premature LH surge may lead to prema-
ture luteinization, which has detrimental effects on preg-
nancy rates [2,3]. Therefore, inhibiting spontaneous
ovulation is critical for successful oocyte retrieval and is
routinely integrated into IVF stimulation protocols.
Current practice utilizes gonadotropin-releasing hormone
(GnRH) agonists or antagonists that act centrally on the
anterior pituitary gland to inhibit the release of LH and
FSH, thus preventing spontaneous ovulation [4]. These
medications are administered subcutaneously on a daily
basis and are associated with prolonged treatment proto-
cols, increased doses of gonadotropins for stimulation and
added costs [5].
The intrinsic pulsatile secretion of GnRH has been di-
rectly associated with rhythmic changes in intracellular
calcium concentration in GnRH neurons within thetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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secretion can be markedly dampened using calcium chan-
nel blockers (CCB). It was noted that nifedipine, a CCB,
inhibited the calcium dependent depolarization of clonal
pituitary gonadotrophic cells in-vitro [7,8]. Furthermore
direct injection of nifedipine into the preoptic area of the
brain completely abolished the LH surge in proestrus rats
[9]. However, due to its relatively hydrophilic nature,
nifedipine has minimal ability to cross the blood–brain
barrier to elicit an inhibitory effect on the GnRH neurons
in clinical practice [10].
On the other hand, nimodipine (Nimotop; Bayer,
Mississauga, ON) is a lipophilic CCB that is able to cross
the blood–brain barrier [11]. Nimodipine is currently
approved to reduce the severity of neurological deficits
in patients who have had a recent subarachnoid
hemorrhage (SAH) [12]. On a cellular level, nimodipine
has been shown to inhibit the pulsatile activity of GnRH
gene expression [13], an intrinsic property of GnRH
neurons that is necessary for proper initiation of the LH
surge. Specifically, nimodipine blocks L-type voltage
gated calcium channels, which prevent the influx of
extracellular calcium and subsequently the stimulation
of GnRH release [8,14,15]. A recent animal study by our
group demonstrated that oral administration of nimo-
dipine to mice in the metaestrus phase resulted in a no-
ticeable inhibition of ovulation in a dose related manner
[16].
Due to its ability to cross the blood–brain barrier and
suppress the calcium dependent pulsatile GnRH release,
we proposed that nimodipine might inhibit the spontan-
eous mid-cycle LH surge and potentially serve as an in-
expensive oral alternative to GnRH agonist or antagonist
medications. The present study was a proof of principle
pilot study to determine the safety and effectiveness of
nimodipine to delay the mid-cycle spontaneous LH surge
in reproductive-aged women with regular menstrual
cycles.
Methods
This was a prospective observational pilot study with
Mount Sinai Hospital Research Ethics Board (MSHREB)
approval (90-0175-A). Written informed consent was
obtained from the participants of this study. Eight healthy
reproductive-aged women with regular menstrual cycles
were enrolled in the study.
Our inclusion criteria included women age ≥18 years
old with regular menstrual cycles for a minimum of
three consecutive months as defined by a cyclical pattern
of menses ranging between 21 to 35 days or clinical
evidence of monthly ovulation. We excluded women
who were actively trying to conceive, currently pregnant,
had a delivery within the last six months or actively
breastfeeding. Any condition that could lead to non-ovulatory menstrual cycles, including the current use of
hormonally based contraception of any form, was also
an exclusion criterion.
Study subjects were recruited voluntarily from the com-
munity through advertisements at Mount Sinai Hospital,
Toronto. The screening process for enrollment was con-
ducted during scheduled appointments at the Toronto
Center for Advanced Reproductive Technology (TCART)
during the period of July 2010 to September 2010. An
evaluation of the patient’s medical history was conducted
to ensure all inclusion and exclusion criteria were met. All
subjects were provided a complete package that included
nimodipine capsules, LH urine test kits and a booklet to
assist the patient in documentation and to facilitate accu-
rate data retrieval (Table 1).
Participants self-monitored three consecutive menstrual
cycles with respect to menstrual onset and duration. The
subjects also monitored the presence or absence of a na-
tural LH surge using the LH urine test kit (First Response
Easy Read Ovulation Test, Princeton, NJ) during all three
cycles. The LH test was performed daily at the same time
starting from the mid-follicular phase of the cycle until an
initial positive test was detected.
The first and third cycles were completely observatory;
self-monitoring booklet and LH urine test kit only. Each
patient served as her own control, and an expected LH
surge cycle day was determined based on the results of
the first cycle. In the second cycle subjects took nimodi-
pine 60 mg (two 30 mg capsules) orally three times daily
for a total of four days (or until a positive LH surge was
recorded), starting two days before the expected LH
surge cycle day.
If a participant surged “prematurely” in their second cycle
(prior to the initiation of nimodipine – two or more days
prior to the expected LH surge day) then nimodipine was
withheld and the cycle was used as an additional observa-
tory cycle. In this scenario we used the average LH
cycle day from the first two cycles as the new expected LH
surge cycle day and the study resumed as per protocol. If a
positive LH surge occurred in the four-day period of taking
nimodipine (cycle 2), the medication was discontinued and
the participant continued to self-monitor the cycle as
planned.
The primary outcome measure was LH surge delay
(cycle 2 positive urine LH day – cycle 1 or 3 positive urine
LH day). Cycle length was calculated from the first day of
menstruation to the subsequent first day of menstruation.
Patient compliance with the medication and any side
effects were documented using a standardized question-
naire. Data were analyzed using SPSS. Comparisons of LH
surge day and cycle lengths between cycles were per-
formed using paired t-tests.
Informed consent was obtained from all participants
prior to the start of the study. Monetary compensation
Table 1 Monitoring chart given to patients: mock chart completed
Cycle Day 10 Day 11 Day 12 Day 13 Day 14 Day 15
1 LH - LH - LH - LH +
2
Nimodipine Nimodipine Nimodipine Nimodipine
Expected LH surge
LH - LH - LH - LH - LH - LH +
3 LH - LH - LH - LH +
Nimodipine was taken 2 days before the expected LH surge as determined by the 1st menstrual cycle and continued for a total of 4 days. In this mock patient, the
LH surge was noted on Day 13 during the first and third cycle, but on Day 15 during the second (nimodipine) cycle.
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Since this was a proof-of-principle pilot study on human
subjects, we minimized drug exposure by using the lo-
west published effective dose and restricting the sample
size under the guidance of the MSHREB.
Results
There were a total of eight patients who fulfilled study
criteria with an average age of 35.8 +/− 7.5 years old.
There were 23 monitored cycles with a documented LH
surge as one patient had a presumed anovulatory 3rd
cycle (absence of an LH surge). Five out of eight patients
had their spontaneous LH surge delayed by at least one
day during the nimodipine cycle (range 0–4 days) in
comparison to the initial observatory cycle (Table 2).
The LH surge was significantly delayed in the nimodi-
pine cycle relative to both observatory cycle 1 (N = 8,
15.5+/− 3.4 days vs 14.0+/− 2.8 days, p = 0.033; Figure 1)
and cycle 3 (N = 7, 15.1+/− 3.5 days vs 13.1+/− 2.4 days
p = 0.044; Figure 2). There was no difference in the LH
surge day between cycle 1 and cycle 3 (N = 7; 13.4+/−
2.4 days vs N = 7; 13.1+/− 2.4 days; p = 0.457).
There was no statistical difference in the mean cycle
lengths between the interventional cycle (cycle 2: mean
28.4+/− 2.8 days) and either of the observational cycle 1
(mean 28.1+/− 2.7 days; p = 0.598) or cycle 3 (mean
27.4+/− 2 days; p = 0.259). No menstrual cycle irregular-
ities were reported in the nimodipine cycle. In the third
cycle one patient had an anovulatory cycle and one pa-
tient reported two days of spotting after their LH surge,Table 2 LH surge day, by cycle








8 10 11while the rest of the participants reported regular cycles
throughout the study.
There was complete medication compliance among
study participants. Three out of eight subjects experienced
headaches that were temporally associated with nimodi-
pine administration. Headaches began within 1–2 hours of
taking the drug (n = 2) or that same evening (n = 1). The
duration of the headaches was on average 2.2 days (range
1–4 days) and the pain level was rated an average of 5.3
on a scale of 0–10 (range 4–7). Over the counter medica-
tion was effective in alleviating headaches in all subjects
and their symptoms subsided upon discontinuation of
nimodipine. One patient reported brief shortness of breath
and tachycardia temporally associated with pill intake.
Symptoms were more intense in the morning and were
alleviated slightly by reducing caffeine intake. Another
patient reported fatigue and drowsiness that she believed
to be a result of nimodipine ingestion, which was more
severe at night. Both subjects reported that their symp-
toms abated upon discontinuation of medication. How-
ever, all participants classified nimodipine as a medication
with tolerable side effects.
Discussion
Our results show that there was a significant delay in
the spontaneous LH surge in the cycle in which patients
took nimodipine in comparison to both observatory
cycles, with no effect on overall cycle length. Further-
more nimopidine was generally tolerable, with only mild



















Figure 1 LH surge of 8 female patients (mean ± SD). The LH
surge in the nimodipine cycle was significantly delayed in comparison to
observatory cycle 1 (mean 15.5 ± 3.4 days vs 14.0 ± 2.8 days, p = 0.033).
**Comparisons of LH surge day between cycles were performed using
paired t-tests.
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on assessing the safety and effectiveness at the lowest
therapeutic dose and duration in the minimum number
of required participants. While patients took nimodipine
for a period of four days, only two days of treatment
occurred beyond the expected LH surge day based on
the first cycle (Table 1). Therefore complete efficacy in
delaying the LH surge represented a maximum two-day
delay in the treatment cycle. In total, five out of eight
patients had an intended delay of a spontaneous LH
surge by at least one day during their nimodipine cycle.











Figure 2 LH surge of 7 female patients (mean ± SD). The LH
surge was significantly delayed in the nimodipine cycle 2 in comparison
to observatory cycle 3 (mean 15.1 ± 3.5 days vs 13.1 ± 2.4 days,
p = 0.044). Among the eight patients, one patient had an anovulatory
3rd cycle and did not have a positive LH surge. **Comparisons of LH
surge day between cycles were performed using paired t-tests.the same as the first cycle. None of the patients had an
LH surge in the two day window prior to the expected
LH surge day (Table 2).
Patients undergoing intra-uterine insemination (IUI)
cycles, with or without ovarian stimulation, don’t rou-
tinely utilize any medical suppression of the natural LH
surge. Not surprisingly, these cycles have a high preva-
lence of premature LH surge, commonly defined as a
natural LH surge occurring before the leading ovarian
follicle reaches 18 mm in diameter. In a recent study of
87 monitored IUI cycles patients were administered
clomiphene citrate (CC) (60%), letrozole (16%) or no
ovarian stimulation (24%), and 28.7% had a premature
LH surge, with no significant difference among the three
groups [17]. In a similar study, patients were randomized
to CC or recombinant follicle-stimulating hormone
(rFSH) coupled with IUI. Among 153 monitored cycles
36% demonstrated a premature LH surge [18].
Given the prevalence of premature LH surge with
ovarian stimulation, medical suppression of the physio-
logical LH surge is routinely used in IVF cycles, which
results in lower cancellation rates and improvement in
routine organization. In current practice the LH surge is
inhibited by GnRH agonists or antagonists, both of
which ultimately suppress pituitary gonadotropin secre-
tion [4]. Both these treatment options increase the need
for multiple injections resulting in increased patient dis-
comfort, inconvenience and overall costs [5]. Hence, an
inexpensive oral medication, such as nimodipine, would
be welcomed as a more convenient and cost effective
approach if shown to be efficacious in preventing prema-
ture LH surges in ART protocols. Even in IUI cycles,
where ovulation suppression is not used, there may be a
pregnancy benefit to delaying the LH surge. A recent
publication has demonstrated that the optimal follicle
size on ultrasound to achieve pregnancy in clomiphene
citrate or letrozole cycles is 2.5 cm rather than 1.8 cm
[19]. Nimodipine is a relatively lipophillic calcium chan-
nel blocker that crosses the blood brain barrier to exert
its effects intracerebrally [11]. This property makes
nimodipine an ideal candidate for an oral medication to
affect GnRH neurons. There is strong evidence that
nimodipine can suppress GnRH release on a cellular
level [8,14,15] and prevent ovulation in mice [16].
Numerous other hormones [20-23], peptides [24,25]
and endotoxins [26] have been explored as candidates to
suppress a premature LH surge, but studies have been
restricted to animal studies and clinical evidence is
lacking.
Several reproductive-associated hormones, such as
progesterone and mifepristone (anti-progesterone) have
been investigated in human subjects. One clinical trial
examined the effect of a five-day mid-cyle course of ethi-
nyl estradiol and norethindrone on 10 volunteers with
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surge or evidence of ovulation, while ultrasound findings
suggested appropriate follicular growth and endometrial
thickening [27]. In another small study of nine patients
serving as their own controls, subjects were stimulated
with rFSH in the initial cycle and with FSH and mife-
pristone in the subsequent cycle. An endogenous LH
surge was noted in 6/9 patients in the first cycle, but
none in the second. The major drawback was mifepris-
tone’s adverse effect on folliculogenesis and decreased
estradiol and progesterone levels in the luteal phase [28].
A more recent pilot study of 15 healthy oocyte donors
undergoing ovarian stimulation for IVF investigated the
effectiveness of daily mifepristone in comparison to
GnRH agonist to prevent premature LH surge. Although
no statistical analysis was published, it was noted that
none of the ten subjects treated with 40 mg mifepristone
daily had a premature surge while one of the five GnRH
agonist patients had premature luteinization. However,
endometrial biopsies in these patients demonstrated that
mifepristone had a negative impact on endometrial
receptivity at the gene level, even with progesterone
supplementation [29]. The clinical utility of progesterone
and mifepristone supplementation during an ovarian
stimulation cycle, with the aim of inhibiting an LH
surge, must be questioned as it may mimic premature
luteinzation or adversely affect implantation [2,3]. There
is currently no effective alternative to GnRH analogues
to inhibit the spontaneous LH surge in women under-
going ovarian stimulation.
It is imperative to keep in context the limitations of our
single-arm pilot study composed of a small sample size of
unblinded healthy participants. On the other hand, there
does appear to be a significant temporal association
between nimodipine and LH surge delay as patients served
as their own controls, pre and post-intervention. Further-
more the rationale to use nimodipine to inhibit an LH
surge is solidly based on both in vitro and in vivo animal
research. Unlike other medications investigated in clinic
settings, nimodipine is not a hormone and thus may have
a more isolated effect on the LH surge, although this has
yet to be proven. Furthermore it is an inexpensive oral
medication with a high safety profile that could potentially
be used to prevent a spontaneous LH surge.
In our study subjects received 60 mg only every eight
hours for a total of four days and there were no reported
cases of severe side effects. While three out of eight
patients experienced a headache that was associated with
nimodipine intake, conservative measures were effective
in reversing symptoms, which subsided upon discon-
tinuation of nimodipine. Without a placebo comparison
arm it remains difficult to ascertain whether this is the
direct effect of the medication, although it appeared
to be temporally associated. In two double-blindedrandomized controlled trials comparing nimodipine to
placebo there was no difference in side effects [30] and
even an increased adverse event rate in the placebo arm
(RR = 1.29; CI 1.03-1.61) [31]. Interestingly, of the three
patients that experienced a headache, one had an LH
surge delay of three days and another of four days.
Study participants all had a history of regular men-
strual cycles, but there remains a natural intra-patient
variability of LH surge day. We restricted our study
design to investigate a two day delay in order to
minimize drug exposure in this pilot study. It is note-
worthy that nimodipine was initiated two days prior to
the anticipated LH surge and no patients in the medica-
tion cycle had an LH surge in the two day window prior
to the expected date. As well there was no statistical
difference in the LH surge day between the two control
cycles further supporting the stability of the LH surge
day in our subjects.
One drawback to our study design is that if patients
had an LH surge prior to initiating nimodipine (expected
LH surge – 2 days), the interventional cycle was sus-
pended and the data was used as part of a second obser-
vatory cycle, although this only occurred in one patient.
The primary outcome of this study was the LH surge
day. A delayed LH surge, in essence a prolonged follicular
phase, is expected accompany a longer menstrual cycle.
Interestingly our results demonstrated no difference in
cycle length in the nimodpine cycle. We have no expla-
nation for this observation, but perhaps with an
intentional longer LH surge delay we will be able to iden-
tify a corresponding difference in cycle length.
Conclusions
This proof of principle study served to confirm the
safety and effectiveness of nimodipine in delaying the
spontaneous LH surge in women with regular menstrual
cycles. This study has now led to a RCT that is currently
underway to investigate the clinical use of nimodipine as
an alternative to delay the premature LH surge in
women with subfertility undergoing ovarian stimulation
cycles and IUI.
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